Co-Diagnostics, Inc.
CODX
Rank in Stocks
#31868
Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops,... Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is based in Salt Lake City, Utah.
Share Price
$0.319
Last synced: 2026-11-09
Market Cap
$2.38M
Change (1 day)
24.22%
Change (1 year)
-97.14%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Co-Diagnostics, Inc. (CODX)
Category
Healthcare
P/E ratio for Co-Diagnostics, Inc. (CODX)
P/E ratio as of November 2026 TTM: -0.01
According to Co-Diagnostics, Inc.'s latest financial reports and stock price, its current price-to-earnings ratio (TTM) is -0.01. At the end of 2025 the company had a P/E ratio of -0.14.
P/E ratio history for Co-Diagnostics, Inc. from 2014 to 2026
P/E ratio at the end of each year
| Year | P/E Ratio | Change |
|---|---|---|
| 2026 (TTM) | -0.01 | -90.21% |
| 2025 | -0.14 | -76.21% |
| 2024 | -0.60 | -45.28% |
| 2023 | -1.10 | -80.17% |
| 2022 | -5.57 | -179.21% |
| 2021 | 7.03 | 20.24% |
| 2020 | 5.85 | -341.66% |
| 2019 | -2.42 | -18.39% |
| 2018 | -2.97 | -28.66% |
| 2017 | -4.16 | -87.52% |
| 2016 | -33.32 | 5.94% |
| 2015 | -31.45 | -27.77% |
| 2014 | -43.54 | 0.00% |
P/E ratio for similar companies or competitors
| Company | P/E Ratio | P/E Ratio Difference | Country |
|---|---|---|---|
| 32.27 | -235,632.12% |
US
|
|
| -27.78 | 202,706.57% |
US
|
|
| -26.70 | 194,758.39% |
AU
|
|
| 24.36 | -177,936.50% |
BE
|
|
| 42.44 | -309,900.73% |
NL
|
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.
Questions about Co-Diagnostics, Inc.'s P/E ratio
What is Co-Diagnostics, Inc.'s P/E ratio?
Co-Diagnostics, Inc.'s P/E ratio is -0.01, as of Nov 2026.
What was Co-Diagnostics, Inc.'s P/E ratio in 2025?
In 2025, Co-Diagnostics, Inc.'s P/E ratio was -0.14, compared with -0.60 in 2024.
How has Co-Diagnostics, Inc.'s P/E ratio changed since 2020?
From 2020 to 2025, Co-Diagnostics, Inc.'s P/E ratio was highest in 2021 (7.03) and lowest in 2022 (-5.57).
How does Co-Diagnostics, Inc.'s P/E ratio compare with similar companies?
Co-Diagnostics, Inc.'s P/E ratio (-0.01) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with 42.44.